Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
139 JPY | -2.11% | 0.00% | -20.57% |
Business Summary
Number of employees: 92
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research Support
68.3
%
| 1,381 | 61.8 % | 2,018 | 68.3 % | +46.14% |
Medical
31.7
%
| 854 | 38.2 % | 936 | 31.7 % | +9.56% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
50.7
%
| 1,249 | 55.9 % | 1,499 | 50.7 % | +20.00% |
United States
27.3
%
| 509 | 22.8 % | 805 | 27.3 % | +58.22% |
United Kingdom
18.6
%
| 401 | 17.9 % | 549 | 18.6 % | +37.08% |
India
3.4
%
| 76 | 3.4 % | 100 | 3.4 % | +31.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shigetomo Akano
DFI | Director of Finance/CFO | 42 | 20-11-10 |
President | 56 | 04-06-30 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 15-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 61 | 08-05-31 | |
President | 56 | 04-06-30 | |
Daisuke Usui
COO | Chief Operating Officer | 50 | 15-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 89,013,591 | 84,172,185 ( 94.56 %) | 72,256 ( 0.0812 %) | 94.56 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
KRINGLE PHARMA, INC. 1.59% | 100,000 | 1.59% | 348,211 $ |
REPROCELL INCORPORATED 0.04% | 33,700 | 0.04% | 35,405 $ |
Company contact information
ReproCELL, Inc.
Metlife Shin-Yokohama Building, 9/F 3-8-11 Shin-Yokohama
222-0033, Yokohama
+81 45 475 3887
http://www.reprocell.co.jpSector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.57% | 80.14M | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+57.86% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.84B | |
-3.04% | 7.93B |
- Stock Market
- Equities
- 4978 Stock
- Company ReproCELL Incorporated